Literature DB >> 3445125

A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. A study by the Copenhagen Renal Cancer Study Group.

M Kjaer1, P Iversen, V Hvidt, E Bruun, P Skaarup, J Bech Hansen, P L Frederiksen.   

Abstract

Between 1979 and 1984 the Copenhagen Renal Cancer Study Group randomized 72 patients nephrectomized for stages II and III renal adenocarcinoma in a prospective study of postoperative radiotherapy versus observation. Radiotherapy was 50 Gy in 20 fractions to the kidney bed, ipsi- and contralateral lymph nodes. 7/72 were excluded from further analysis because of major protocol violations. 33/65 were in stage II, 32/65 in stage III. Relapse was found in 31/65 = 48% during the follow-up period without any difference between the two groups. 12/27 = 44% had significant complications from stomach, duodenum or liver, median 5 mo., range 1-44 mo. after radiotherapy. In 5/27 = 19% did the postirradiatory complications contribute to the death of the patients. Patients with stage II tumours survived significantly better than those with stage III tumours (p less than 0.05), but no significant differences in survival could be demonstrated between patients randomized to postoperative radiotherapy or observation. It is concluded that postoperative radiotherapy as given in the present study is without any beneficial effect on relapse rate and survival. Moreover, the treatment is associated with an unacceptable complication rate.

Entities:  

Mesh:

Year:  1987        PMID: 3445125     DOI: 10.3109/00365598709180784

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  21 in total

Review 1.  Extracorporeal stereotactic radiosurgery for small renal masses.

Authors:  Gino J Vricella; Nicholas A Boncher; Lee E Ponsky
Journal:  Curr Urol Rep       Date:  2010-02       Impact factor: 3.092

Review 2.  Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach.

Authors:  Shankar Siva; Gargi Kothari; Alexander Muacevic; Alexander V Louie; Ben J Slotman; Bin S Teh; Simon S Lo
Journal:  Nat Rev Urol       Date:  2017-06-20       Impact factor: 14.432

Review 3.  Is there a role for adjuvant therapy after surgery in "high risk for recurrence" kidney cancer? An update on current concepts.

Authors:  T Sharma; C Tajzler; A Kapoor
Journal:  Curr Oncol       Date:  2018-10-31       Impact factor: 3.677

4.  In vivo growth and responses to treatment of renal cell carcinoma in different environments.

Authors:  Yahya Alhamhoom; Guisheng Zhang; Mingming Gao; Houjian Cai; Dexi Liu
Journal:  Am J Cancer Res       Date:  2017-02-01       Impact factor: 6.166

Review 5.  Update on targeted therapies for clear cell renal cell carcinoma.

Authors:  Eric A Singer; Gopal N Gupta; Ramaprasad Srinivasan
Journal:  Curr Opin Oncol       Date:  2011-05       Impact factor: 3.645

Review 6.  Adjuvant therapy for high-risk renal cell carcinoma patients.

Authors:  David A Kunkle; Naomi B Haas; Robert G Uzzo
Journal:  Curr Urol Rep       Date:  2007-01       Impact factor: 3.092

7.  Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma.

Authors:  Vitaly Margulis; Surena F Matin; Nizar Tannir; Pheroze Tamboli; Yu Shen; Marisa Lozano; David A Swanson; Eric Jonasch; Christopher G Wood
Journal:  Urology       Date:  2008-10-31       Impact factor: 2.649

Review 8.  Adjuvant therapy for renal cell carcinoma.

Authors:  Naomi B Haas; Robert Uzzo
Journal:  Curr Oncol Rep       Date:  2008-05       Impact factor: 5.075

Review 9.  Role of radiation therapy for renal tumors.

Authors:  Bhupesh Parashar; Kanhu Charan Patro; Michael Smith; Shruthi Arora; Dattatreyudu Nori; A Gabriella Wernicke
Journal:  Semin Intervent Radiol       Date:  2014-03       Impact factor: 1.513

10.  Salvage robot-assisted partial nephrectomy for the management of renal cell carcinoma following failed stereotactic radiotherapy.

Authors:  Michael A Gorin; Vladislav Gorbatiy; Charles Glenn; Samir P Shirodkar; Scott M Castle; Merce Jorda; Raymond J Leveillee
Journal:  JSLS       Date:  2012 Jan-Mar       Impact factor: 2.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.